stockrow
Friday 6 November 2026
Export SPRO’s income statement to Excel — free account
Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024.
- Revenue
- −95.6%
- EPS
- −433.3%
- Free cash flow
- +69.7%
Quarter to June 2026, against a year earlier
1.04
0.02
+1.96%
Follow SPRO
Alert me
Spero Therapeutics, Inc. (SPRO) P/E ratio
As of 6 November 2026, Spero Therapeutics, Inc. (SPRO) trades at a P/E ratio of 7.4×. Over the past ten years it has ranged from 0.0× (December 2025) to 147× (December 2023); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 15.5× | — |
| FY2024 | 0.0× | — |
| FY2023 | 3.5× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 8.7× | (44.21%) |
| Dec 2025 | 15.5× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 147×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CGTX Cognition Therapeutics, Inc. compare | n/m |
| XBIT XBiotech Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. | 7.4× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)